Severe bronchospasm associated with rituximab for refractory churg- Strauss syndrome

Annals of the Rheumatic Diseases

Volumn 68, Issue 4, 2009, Pages 606-

  Bouldouyre, M A ^a   Cohen, P ^a   Guillevin, L ^a  

^a Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXCHLORPHENIRAMINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; RITUXIMAB; SALBUTAMOL; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALLERGY; ASTHMA; BRONCHOSPASM; CASE REPORT; CATARACT; CHURG STRAUSS SYNDROME; COUGHING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; HYPEREOSINOPHILIA; LETTER; LUNG INFILTRATE; MONONEUROPATHY; MYOPATHY; PARANASAL SINUSITIS; POLYARTHRITIS; PRIORITY JOURNAL; REFRACTORY PERIOD; RESPIRATORY TRACT DISEASE; TREATMENT FAILURE; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BRONCHIAL SPASM; CHURG-STRAUSS SYNDROME; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 65249111549     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.093773     Document Type: Letter

References (10)

1. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007;25(suppl 44):S23-7.
2. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005;257:50-8.
3. Sablé-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. French Vasculitis Study Group. Antineutrophil cytoplasmic antibodies and the Churg- Strauss syndrome. Ann Intern Med 2005;143:632-8.
4. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926-35.
5. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
6. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006;65:1116-17.
7. Koukoulaki M, Smith KGC, Jayne DRW. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006;65:557-9.
8. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008;47:1104-5.
9. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich E, Park K, et al. Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64.
10. National Institutes of Health. ClinicalTrials.gov. Search for clinical trials. www.clinicaltrials.gov (accessed 7 Feb 2009).